Guard Therapeutics is developing innovative therapies focusing on kidney diseases. The company's lead clinical asset, RMC-035, is in phase 2b development for the prevention and treatment of kidney injuries in patients undergoing open heart surgery. The company also has preclinical candidate drugs intended for the treatment of chronic kidney disease, targeting specific disease segments such as FSGS, IgAN, Alport Syndrome and DKD. Listed on Nasdaq First North Growth Market.
View Top Employees from Guard Therapeutics| Website | http://guardtherapeutics.com |
| Employees | 15 (10 on RocketReach) |
| Technologies |
JavaScript,
HTML,
Nginx
+4 more
(view full list)
|
| Industry | Biotechnology Research |
Looking for a particular Guard Therapeutics employee's phone or email?
Guard Therapeutics Questions
Tobias Agervald is the CEO of Guard Therapeutics.
10 people are employed at Guard Therapeutics.
Top Guard Therapeutics Employees
-
25
-
2
-
2
-
2
-
1
-
1
-
Related Companies
